21.00
+0.09
(0.43%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 20.46 - 21.31 |
| 52 week | 14.07 - 31.93 |
| Open | 20.92 |
| Vol / Avg. | 87,534.00/72,027.00 |
| Mkt cap | 386.08M |
| P/E | - |
| Div/yield | - |
| EPS | -3.02 |
| Shares | 18.38M |
| Beta | - |
| Inst. own | 65% |
Events
Jun 4, 2013
Kythera Biopharmaceuticals Annual Shareholder Meeting
- 12:00PM EDT -
May 14, 2013
Kythera Biopharmaceuticals at Bank of America Merrill Lynch Health Care Conference
May 13, 2013
Q1 2013 Kythera Biopharmaceuticals Earnings Conference Call
May 13, 2013
Q1 2013 Kythera Biopharmaceuticals Earnings Release
Mar 5, 2013
Kythera Biopharmaceuticals at Cowen Health Care Conference
Feb 26, 2013
Kythera Biopharmaceuticals at RBC Capital Markets' Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | - | -186.92% |
| Operating margin | - | -182.55% |
| EBITD margin | - | -179.32% |
| Return on average assets | -61.27% | -52.09% |
| Return on average equity | -90.88% | - |
| Employees | 46 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 200 27200 West Agoura Road
CALABASAS, CA 91301
United States - Map
+1-818-5874500 (Phone)
+1-818-5874591 (Fax)
CALABASAS, CA 91301
United States - Map
+1-818-5874500 (Phone)
+1-818-5874591 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Volume delayed by 15 mins.
Advertisement
Description
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company�s initial focus is on the facial aesthetics market. The Company�s product candidate, ATX-101, is a injectable drug in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted, ATX-101 has exhibited results in the reduction of submental fat. ATX-101 contains a synthetic form of sodium deoxycholate. In the United States and Canada, the Company is conducting two pivotal Phase III trials of ATX-101 for the reduction of submental fat. The Company initiated this pivotal Phase III clinical program, with planned enrollment of 1,000 patients, in March 2012.
Officers and directors
| Keith R Leonard Jr. | President, Chief Executive Officer, Director | |
| John W. Smither | Chief Financial Officer | |
| Jeffrey D. Webster | Senior Vice President - Operations | |
| Keith L. Klein J.D. | General Counsel | |
| Frederick Beddingfield III, M.D., Ph.D. | Chief Medical Officer | |
| Dennis M. Fenton Ph.D. | Lead Independent Director | |
| Nathaniel E. David Ph.D. | Independent Director | |
| Francois Kress | Independent Director | |
| Robert T. Nelsen M.D. | Independent Director | |
| Camille D. Samuels MBA | Independent Director |